Collegium Pharmaceutical Inc. (NASDAQ:COLL) fell 4% on Thursday . The stock traded as low as $12.12 and last traded at $12.19, with a volume of 67,697 shares. The stock had previously closed at $12.70.

Several research firms recently weighed in on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 28th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $27.00 price objective (up previously from $26.00) on shares of Collegium Pharmaceutical in a research report on Thursday, June 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective (up previously from $28.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Collegium Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $29.25.

The company has a 50-day moving average price of $13.12 and a 200-day moving average price of $16.46. The company’s market capitalization is $286.79 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.08. Equities analysts forecast that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current fiscal year.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.